Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Pharmaceuticals has received US FDA approval for its Abbreviated New Drug Application (ANDA) for morphine sulfate extended-release capsules USP, the generic equivalent of Actavis' Kadian.
Subscribe to our email newsletter
Kadian is used for management of moderate to severe pain that lasts for an extended period of time.
Following the approval, the company has started shipping the product.
According to a data by IMS Health, Kadian had registered sales of around $275m in the last twelve months ending 30 September 2011.